Key Highlights

  • USD 45.74 billion is the market capitalization of State Street (NYSE:STT), the largest of four oversold names, at USD 166.52 on October 16, 2026, per published market data. The 14-day RSI is 24.1, and consensus 2026 EPS of USD 13.80 implies 12.1 times earnings (own arithmetic).
  • USD 5.92 billion is the market capitalization of Caesars (NASDAQ:CZR) at USD 29.07, against a USD 31.00 per share cash offer from Fertitta Entertainment. The gross spread is 6.6% (own arithmetic), and the RSI of 21.3 conflicts with an October 13 reading of 45.85.
  • USD 4.85 billion is the market capitalization of Oruka Therapeutics (NASDAQ:ORKA) at USD 73.24, which is 1.0% above the USD 72.50 April 28, 2026 offering price (own arithmetic). Cash of USD 1.1 billion equals 22.7% of market capitalization, and the RSI is 29.6.
  • USD 4.80 billion is the market capitalization of Travere Therapeutics (NASDAQ:TVTX) at USD 50.95, which is 26% below its USD 68.73 high (own arithmetic). Filspari net sales rose 96% to USD 141.1 million in the second quarter, and the RSI is 28.9.

State Street (NYSE:STT)

The market priced perfection, and the print offered a rounding error. State Street reported third quarter diluted EPS up 33% to USD 3.69 on October 14, 2026, against a USD 3.68 consensus, while revenue of USD 4.004 billion missed the USD 4.04 billion consensus by 0.9% (own arithmetic). The shares fell 6.5% to USD 162.84 from USD 174.10 and recovered to USD 166.52. What separates it from the other three is earnings power: return on equity reached 16.4%, the standardized CET1 ratio was 11.0%, and 2026 fee revenue growth guidance was raised to 13% to 14%. A custody bank works like a toll road, where volume drives fees and rates drive margin. Net inflows were USD 7 billion and assets under management reached USD 6.306 trillion. The quarterly dividend of USD 0.92 implies a 2.2% yield, and fourth quarter buybacks of USD 700 million equal 1.5% of market capitalization (own arithmetic). The price is 1.5% below the 200-day average of USD 168.99. So what: the reference level is earnings, but guidance assumes flat equity markets, and the Federal Reserve decides on October 28, 2026.

Caesars (NASDAQ:CZR)

The reference level here is written into a contract. Caesars agreed on May 28, 2026 to the USD 31.00 cash purchase, valuing the deal at USD 17.6 billion including USD 11.9 billion of assumed debt. What separates it from the other three is that the anchor is external: shareholders approved on September 22, 2026, but the Federal Trade Commission issued a second request on September 14 and gaming approvals remain. The outside date is May 27, 2027, extendable to November 27, 2027, and a ticking fee of USD 0.00715 per share per day starts after June 26, 2027. Closing on the first outside date would imply a 10.9% annualized gross return (own arithmetic, 223 days, not a forecast). A USD 450 million reverse termination fee applies if antitrust or gaming law blocks the merger. TD Cowen downgraded the stock to Hold on the deal. Without the deal, a trailing net loss of USD 465 million would set the valuation. So what: the spread prices delay and completion risk. Third quarter results are due October 27, 2026.

Oruka Therapeutics (NASDAQ:ORKA)

Strong data and a large balance sheet have not held the price. On September 23, 2026, Oruka reported that 71.4% of patients reached PASI 100, clear skin, at Week 28 of the EVERLAST-A trial, up from 63.5% at Week 16, and shares fell 5% that morning because the data met expectations. What separates it from the other three is that the anchor is a transaction price: the April offering sold 9.66 million shares at USD 72.50 for USD 700.4 million gross. The stock sits 36.6% below its USD 115.52 high (own arithmetic). The first-half net loss of USD 73.0 million annualizes to USD 146 million, a 7.5-year runway on USD 1.1 billion before Phase 3 costs (own arithmetic). Consensus is Strong Buy from 13 analysts with a USD 155.00 average target, 111.6% above the price (own arithmetic). The offering price is a reference level, not a floor. So what: Week 16 data from the 187-subject EVERLAST-B trial are due in the fourth quarter, and an adverse readout would reprice the stock.

Travere Therapeutics (NASDAQ:TVTX)

A growing launch meets a leadership change. Filspari net sales of USD 141.1 million were up from USD 71.9 million, total revenue was USD 169.6 million, and the net loss was USD 34.8 million, per the August 4, 2026 release. Chief executive Eric Dube announced on September 21 that he will step down, and Bradley Campbell is named successor from December 1. What separates it from the other three is the revenue base: it is the only one of the four with a launch growing 96%. Annualizing second quarter revenue gives a price to sales multiple of 7.1, and cash of USD 489.2 million equals 10.2% of market capitalization (own arithmetic). The one-week change is only negative 2.09%, and no negative company disclosure was found. Consensus is Strong Buy from 15 analysts with a USD 75.21 average target. So what: ASN Kidney Week presentations run from October 21 to 25, 2026, and results are estimated for October 29.

Where Things Stand

It depends on the type of anchor. State Street (NYSE:STT) has the firmest earnings-based reference level, at 12.1 times consensus earnings with a 16.4% return on equity. Caesars (NASDAQ:CZR) has the most explicit price reference at USD 31.00 in cash, with a 6.6% spread. State Street faces market and rate risk, Caesars faces regulatory timing, and the two biotechs face binary data. Cash as a share of market capitalization is 22.7% at Oruka (NASDAQ:ORKA) and 10.2% at Travere, own arithmetic. Reference levels are not floors, and RSI is not a forecast. Next dated events: Caesars on October 27, the Federal Reserve on October 28 and Travere on October 29, 2026.